Orchid Chemicals net down to Rs 9.51 cr; turnover at 346.45 cr
By Our Corporate Bureau | 28 Jan 2003
Chennai: The city-based cephalosporin bulk drug major Orchid Chemicals and Pharmaceuticals has posted a net profit of Rs 9.51 crore for the nine months ended December 2002 on a turnover of Rs 346.45 crore.
Compared to the previous year's nine-month figures, the company's bottomline has thinned by Rs 91 lakh, while the turnover went up by Rs 68 crore.
For the period under review, the bulk drug sales accounted for Rs 318.94 crore while formulations contributed Rs 41.54 crore. The formulations business, for the first time, has shown a profit of Rs 2.55 crore.
The total expenditure was up by Rs 66.9 crore to Rs 276.70 crore. Similarly the company's interest outgo also went up by Rs 3 crore to Rs 28.04 crore compared to the corresponding period of the previous year.
For the third quarter October-December 2002, the company's turnover went up by Rs 32.57 crore to Rs 128.28 crore as compared to the corresponding period of the previous year. The net profit for the third quarter shows an increase of Rs 1.46 crore to Rs 3.71 crore as compared to the previous year's figures.
Latest articles
Featured articles
Post-splashdown: What Artemis II taught us about the ‘deep space wall’
By Axel Miller | 15 Apr 2026
Artemis II splashdown marks a breakthrough in deep space exploration. Discover AVATAR radiation data, Orion’s distance record, and insights shaping NASA’s 2028 Moon mission.
Can aviation go green? The multi-billion dollar race for sustainable fuel
By Cygnus | 10 Apr 2026
Airlines are racing to adopt sustainable aviation fuel, but limited supply and high costs challenge the future of green aviation.
The battery race: who will control the future of electric vehicles?
By Axel Miller | 08 Apr 2026
The global battery race is reshaping the electric vehicle industry, with China, the US, and Europe competing for control over supply chains and technology.
AI vs governments: Who controls the future of intelligence?
By Cygnus | 07 Apr 2026
Governments and AI companies like OpenAI and Anthropic are shaping the future of intelligence amid rising policy conflicts and global competition.
Strait of Hormuz: how one chokepoint controls the global economy
By Axel Miller | 06 Apr 2026
The Strait of Hormuz is a critical global chokepoint. Learn how disruptions impact oil prices, shipping, and the global economy.
The $2 trillion AI infrastructure race: Who will control global compute?
By Cygnus | 06 Apr 2026
AI spending is set to exceed $2 trillion in 2026, driving a global race in data centers, chips, and energy infrastructure.
Artemis II and the economic outlook for lunar infrastructure
By Axel Miller | 01 Apr 2026
Artemis II will test deep-space systems and support future lunar missions, shaping the next phase of the global space economy.
Synthetic diplomacy: The $50 billion mirage and the new era of market-moving deepfakes
By Cygnus | 30 Mar 2026
Synthetic diplomacy shows how deepfakes could trigger market volatility, highlighting the growing need for verification in global financial systems.
AI war shifts gears: chips, drones reshape global power
By Cygnus | 27 Mar 2026
AI competition is shifting as chips, drones and supply chains reshape global power, impacting tech, defense and business strategies.


